Live Chart

O 28855.8

H 28855.8

L 28855.8

VOL 5

Abbott India Performance

Days Range

Low: ₹28,557.00
High: ₹28,989.15
Previous Close ₹28,855.80
Open ₹28,855.80
Volume 8,695
Day’s Range ₹28,557.00 - ₹28,989.15
52W Range ₹19,906.00 - ₹29,638.95
Market Cap ₹61,361 Cr

Fundamentals of Abbott India

ROCE (TTM) NA
P/E Ratio (TTM) NA
P/B Ratio NA
Industry P/E NA
Debt to Equity NA
ROE NA
EPS (TTM) NA
Dividend Yield NA
Book Value NA
Face Value NA

Financials of Abbott India

Financials data is not available for Abbott India. Please visit after some time.

About Abbott India

History

Abbott India Ltd. is one of the leading multinational pharmaceutical companies in India. It operates with an owned manufacturing facility in Goa and various independent contract/third-party manufacturers based across the country. Abbott India Ltd was originally incorporated on August 22, 1944, as Boots Pure Drug Company (India) Ltd. On July 1, 2002, they got their present name, Abbott India Ltd. 

In the year 2004, the company started the production of capsules and nutritional products. During the financial year ended March 31, 2016, Abbott India launched 17 new products in various therapy segments, which together contributed 1.9% of the net sales of the company. In the same year, the company entered into a licensing arrangement with Bharat Biotech India Limited to market vaccines in the immunology segment. During FY 2019, the company executed 25 new studies and published 45 articles in major indexed journals, with 6 international presentations.

During the year 2022, the company continued portfolio expansion and launched 10 new differentiated products in the market to meet increasing healthcare needs. It increased presence in high-growth therapy areas such as adult vaccination and new sub-therapies like menopause. 

Business Segments

Abbott India provides products and solutions across various therapeutic areas such as Women’s Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc. Its global products include Brufen, Prothiaden, Thyronorm and Leptos.

The company has four divisions:

  1. The Primary Care division markets products in the areas of pain management and gastroenterology. 
  2. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia. 
  3. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments.
  4. Hospital Care offers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta.

Subsidiaries

The company does not have any subsidiaries as of March 31, 2023.

Key Personnel

Mr. Munir Shaikh, Chairman

Mr. Sheikh joined Abbott in 1968 and has served in several management positions with Abbott Asia, Latin America and the United States, including as General Manager in Pakistan, as Director of Business Development, Regional Director of Pacific / Asia / Africa, etc. 

Mr. Vivek V Kamath, Managing Director

Mr. Kamath has over 30 years of rich and diversified experience in healthcare, including pharmaceuticals, OTC and diagnostics. Prior to joining the Company, Mr Kamath worked as the General Manager of the Specialty Care business of Abbott Healthcare Private Limited. Prior to Abbott, he worked with MSD Pharmaceuticals; Roche Diagnostics, India; Novartis, Singapore; Ranbaxy; Pfizer, India; Fulford, India; Wockhardt and Johnson & Johnson.

Corporate Actions

The company has not performed any rights issue, bonus issue, stock split or buyback in recent years.

Mergers and Acquisitions

  • In 2010, the company’s board of directors approved the draft scheme for the amalgamation of Solvay Pharma India into Abbott India.
  • In the year 2003, the company’s wholly-owned subsidiary company, Lenbrook Pharmaceuticals Ltd, was amalgamated with the company.

Financial Performance

  • The company has increased its sales by 30.68% from ₹4,093 crore in FY 2020 to ₹5,349 crore in FY 2023.
  • In the same period, its operating profit margin increased from 18% to 23%.
  • In the aforementioned period, its positive cash flow has also increased from ₹8 crore to ₹107 crore.
Parent Organisation MNC Asc-Abbott
Founded 1944
Managing Director Munir Shaikh
NSE Symbol ABBOTINDIA

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Ajanta Pharma Ltd ₹26,701.26

2125.85

5.85 (0.28%)

2112.35 - 2135
Lupin Ltd ₹72,579.89

1615

21.25 (1.33%)

1597.05 - 1625
Gland Pharma Ltd ₹31,280.19

1861.1

37.55 (-1.98%)

1836.15 - 1915.95
Syngene International Ltd ₹30,090.82

744.5

3.65 (-0.49%)

738.95 - 752.7
Alkem Laboratories Ltd ₹64,795.26

5421.15

2.05 (-0.04%)

5355 - 5472.1

What's Trending

FAQs

What is the Share price of Abbott India (ABBOTINDIA)?

Abbott India (ABBOTINDIA) share price as of February 23, 2024, on NSE is Rs 28,563.05 (NSE) and Rs 28,531.10 (BSE) on BSE.

Can I buy Abbott India (ABBOTINDIA) shares?

Yes, You can buy Abbott India (ABBOTINDIA) shares by opening a Demat account with Angel One.

How do I buy Abbott India (ABBOTINDIA) from Angel One?

Abbott India (ABBOTINDIA) share can be brought through the following modes:
  1. Direct investment: You can buy Abbott India (ABBOTINDIA) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Abbott India (ABBOTINDIA) shares.

Is Abbott India a Debt free Company?

Yes, Abbott India is a debt free company.

What is the main business of Abbott India?

The main business of Abbott India is to offer high-quality medicines in therapeutic categories, including women’s health, cardiology, primary care, gastroenterology, and metabolic disorders.

Who are the promoters of Abbott India?

The primary promoters of Abbott India are Abbott Capital India Limited, Abbott Healthcare Products Limited, and British Colloids Limited.

What are the peers of Abbott India?

The top 5 peers of Abbott India are GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Ltd, Sanofi India Ltd, AstraZeneca Pharma India Ltd. and Procter & Gamble Health Ltd.